Indaptus Therapeutics Stock (NASDAQ:INDP)

Ownership Financials Chart

Previous Close

$1.76

52W Range

$1.52 - $21.84

50D Avg

$2.16

200D Avg

$4.72

Market Cap

$2.98M

Avg Vol (3M)

$648.74K

Beta

0.97

Div Yield

INDP Company Profile

Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Aug 04, 2015

Website

INDP Performance

INDP Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-19.83M	$-15.37M	$-16.38M
Net Income	$-20.85M	$-15.02M	$-15.42M
EBITDA	$-19.83M	$-15.37M	$-16.38M
Basic EPS	$-21.58	$-1.61	$-1.84
Diluted EPS	$-21.58	$-1.61	$-1.84

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
PBM	Psyence Biomedical Ltd.
GTBP	GT Biopharma, Inc.
SLXN	Silexion Therapeutics Ltd.
REVB	Revelation Biosciences, Inc.
PTIX	Protagenic Therapeutics, Inc.